BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 14595509)

  • 21. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
    Giordano G; Gnetti L; Merisio C; Melpignano M
    Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
    Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
    Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
    Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
    Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of preoperative endometrial sampling diagnosis for predicting the final pathology grading in uterine endometrioid carcinoma.
    Batista TP; Cavalcanti CL; Tejo AA; Bezerra AL
    Eur J Surg Oncol; 2016 Sep; 42(9):1367-71. PubMed ID: 27052799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
    Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
    J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium.
    Niikura H; Sasano H; Kaga K; Sato S; Yajima A
    Hum Pathol; 1996 Mar; 27(3):282-9. PubMed ID: 8600044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytologic scoring of endometrioid adenocarcinoma of the endometrium.
    Nishimura Y; Watanabe J; Jobo T; Hattori M; Arai T; Kuramoto H
    Cancer; 2005 Feb; 105(1):8-12. PubMed ID: 15597380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].
    Pilka R; Mícková I; Lubuský M; Dusková M; Rícánková M; Kudela M
    Ceska Gynekol; 2008 Jul; 73(4):222-7. PubMed ID: 18711961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of hPEBP4 negatively correlates with estrogen and progesterone receptors in endometrial carcinoma.
    Guo T; Li B; Gu C
    J BUON; 2013; 18(2):465-70. PubMed ID: 23818363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between expression of p53/bcl-2 and clinicopathological criteria in endometrioid adenocarcinomas of the endometrium.
    Sari I; Gocmen A; Bitiren M; Cakmak EA
    Eur J Gynaecol Oncol; 2004; 25(1):79-80. PubMed ID: 15053067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients.
    Wang X; Huang Z; Di W; Lin Q
    Arch Gynecol Obstet; 2005 Jul; 272(2):136-41. PubMed ID: 15666177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
    Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ
    Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma.
    Yadav A; Sistla A; Swain M; Gowrishankar S; Padua M; Modi T; Himabindu R; Agarwal N; Kulkarni A; Bhandari T; Vudayaraju H; Chinnababu ; Reddy VA
    Indian J Pathol Microbiol; 2024; 67(1):62-67. PubMed ID: 38358190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Sep; 29(9):924-31. PubMed ID: 9744308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.